Jiangsu Hengrui Pharmaceuticals and Bristol Myers Squibb Co signed licensing deals worth up to $15.2 billion in potential milestone payments. The agreement covers 13 early-stage drug programs across oncology, immunology, and blood diseases in China and the United States. Jiangsu Hengrui and Bristol Myers Squibb will exchange global and regional rights to early-stage pharmaceutical assets.

Global Rights Exchange for 13 Pipeline Assets